Assertio Holdings, Inc. (ASRT)
| Market Cap | 116.45M |
| Revenue (ttm) | 118.71M |
| Net Income (ttm) | -30.38M |
| Shares Out | 6.46M |
| EPS (ttm) | -4.74 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 108,959 |
| Open | 18.05 |
| Previous Close | 18.04 |
| Day's Range | 18.03 - 18.07 |
| 52-Week Range | 8.61 - 20.45 |
| Beta | 0.43 |
| Analysts | Hold |
| Price Target | 18.00 (-0.22%) |
| Earnings Date | May 8, 2026 |
About ASRT
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older;... [Read more]
Financial Performance
In 2025, Assertio Holdings's revenue was $118.71 million, a decrease of -5.00% compared to the previous year's $124.96 million. Losses were -$30.38 million, 40.7% more than in 2024.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ASRT stock is "Hold." The 12-month stock price target is $18.0, which is a decrease of -0.22% from the latest price.
News
Assertio Provides Update on Garda Therapeutics Tender Process
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today provided an update that Garda Therapeutics, Inc. (“Garda”) intends to commence the tende...
Cosette Pharmaceuticals Expands Branded Portfolio through Acquisition of SYMPAZAN® and Additional Products from Assertio
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today the closing of a definitive agreement to acquire the U.S. sal...
Assertio Announces Agreement to be Acquired by Garda Therapeutics
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced a definitive agreement (the “Garda Agreement”) to be acquired by Garda Therape...
Top 2 Health Care Stocks That May Implode In April
As of April 1, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Assertio Holdings Earnings Call Transcript: Q4 2025
ROLVEDON remains the primary growth driver, with 2026 guidance reflecting normalized sales and margin expansion. Indocin faces expected declines from generic competition, while disciplined capital allocation and a robust oncology-focused commercial platform position the company for future growth.
Assertio Reports Fourth Quarter and Full Year 2025 Financial Results
LAKE FOREST, Ill--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated pro...
Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio”) (Nasdaq: ASRT) today announced that it will release fourth quarter and full year 2025 financial results on Monday, March 16, 20...
Assertio Holdings, Inc. Regains Compliance With Nasdaq Listing Requirements
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) t...
Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that results of a clinical trial investigating a novel dosing schedule of Rolve...
Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it filed a certificate of amendment to its certificate of incorporation (t...
Assertio Holdings Earnings Call Transcript: Q3 2025
Strong Q3 results driven by a Rosedown sales pull forward led to higher revenue and EBITDA, with guidance narrowed for 2025. Rosedown and Synthesan showed growth, while Indocin faced generic pressure. Cash flow will temporarily dip due to sales timing.
Assertio Reports Third Quarter 2025 Financial Results
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated pr...
Assertio Announces Leadership Transition
Appoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the...
DEADLINE NEXT WEEK: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Contact the Firm Before September 24, 2025
PHILADELPHIA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (“Spect...
Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV
BALTIMORE, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differe...
Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association
LAKE FOREST, Ill., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering...
Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025
LAKE FOREST, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) announced that members of its management team will host investor meetings at ...
Assertio Holdings Earnings Call Transcript: Q2 2025
Q2 2025 saw $28.8M in sales, strong ROLVEDON and SYMPAZAN growth, and improved adjusted EBITDA. Legal settlements, Otrexup exit, and cost actions sharpened focus on core assets, with guidance narrowed and profitability outlook raised.
Assertio Reports Second Quarter 2025 Financial Results
Second Quarter Total Net Product Sales of $28.8 Million, Cash and Investments Increase to $98.2 Million Narrows Guidance on Continued Progress Implementing Long-Term Business Strategy LAKE FOREST, Ill...
Berger Montague PC Investigating Claims on Behalf of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors
PHILADELPHIA , Aug. 6, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum"...
Assertio Holdings, Inc. to Report Second Quarter 2025 Financial Results on August 11, 2025
LAKE FOREST, Ill., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release second quarter 2025 financial results on ...
Assertio Holdings Transcript: Alliance Global Partners Healthcare Company Showcase
A transformation-focused specialty pharma is prioritizing growth assets Rolvedon and Sympazan, reducing legal exposure, and pursuing M&A to drive future expansion. Financial guidance is maintained, with Rolvedon expected to expand market share and new strategic deals anticipated.
Assertio to Participate in the Alliance Global Partners Healthcare Company Showcase on May 21, 2025
LAKE FOREST, Ill., May 19, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that Brendan O'Grady, Chief Executive Officer, will present at ...
Assertio Holdings Earnings Call Transcript: Q1 2025
Q1 2025 sales were $26M, with gross margin at 70% and adjusted EBITDA at $0.2M. Legal liabilities were largely divested, and guidance for 2025 remains unchanged, with growth expected from ROLVEDON and Sympazan as payer coverage expands.
Assertio Reports First Quarter 2025 Financial Results
First Quarter Total Net Product Sales of $26.0 Million, In Line with 2025 Outlook